GLSI
Greenwich LifeSciences, Inc.
Set alert
17.41 USD -1.59 -8.37%
17.08 Day range 18.77
7.85 52-week range 33.56
- YTD
- -17.13%
- 1 year
- +89.45%
- Open
- 18.47
- Prev close
- 19.00
- Mkt cap
- 255.55M
- Vol
- 174.65K
- Avg vol
- 126.59K
- EPS
- -1.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.08
- High
- 18.77
- Forward P/E
- -14.83
- Beta
- 3.32
- Short ratio
- 21.41
- Inst. own
- 8.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 13.57
- 200-d avg
- 14.65
- 1y target
- 38.00
Key statistics
- Market cap
- 159.84M
- Enterprise value
- 171.41M
- Trailing P/E
- 0.00
- Forward P/E
- -14.83
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 23.30
- EPS (TTM)
- -0.81
- Beta
- 3.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -3.15M
- Total cash
- 7.22M
- Total debt
- 0
- Return on equity
- -123.67%
- Shares outstanding
- 13.14M
- Short % of float
- 7.83%
- 50-day average
- 13.57
- 200-day average
- 14.65
Analyst view
Consensus: none
Price target (mean) 38.00
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
GLSI Revenue — quarterly 0
GLSI Net income — quarterly -3.95M
GLSI EPS — quarterly -0.27
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.21 | -0.20 | +0.01 | +4.76% |
| Aug 14, 2024 | Jun 1, 2024 | -0.20 | -0.20 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.20 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.20 | -0.19 | +0.01 | +5.00% |
| May 20, 2024 | Mar 1, 2024 | -0.20 | — | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 10, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Sep 1, 2021 | HC Wainwright & Co. | init | — | Buy |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- greenwichlifesciences.com
News
- Greenwich LifeSciences (NASDAQ:GLSI) Stock Falls 2.1% – Time to Sell?
- 20 stocks likely to lose money even if the bull market continues
- Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027
- Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
- Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
- HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69
- Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going Forward
- Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
- Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe
- Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
Your note
Sign in to keep a note on GLSI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| PATEL SNEHAL | Chief Executive Officer | Purchase | Sep 25, 2024 | 5,536,100 |
| THOMPSON JAYE L | Officer | Purchase | Nov 20, 2024 | 264,148 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.66% | 350,144 | 4.26M | Sep 29, 2024 |
| Vanguard Group Inc | 2.08% | 273,525 | 3.33M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 133,550 | 1.62M | Sep 29, 2024 |
| Credit Agricole S.A. | 0.66% | 87,000 | 1.06M | Sep 29, 2024 |
| Northern Trust Corporation | 0.57% | 74,500 | 905.92K | Sep 29, 2024 |
| State Street Corporation | 0.54% | 71,408 | 868.32K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.17% | 153,459 | 1.87M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.08% | 141,696 | 1.72M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.54% | 71,311 | 867.14K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.47% | 61,696 | 750.22K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.39% | 50,661 | 616.04K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.25% | 32,217 | 391.76K | Oct 30, 2024 |